Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia

Longzhen Cui, Zhiheng Cheng, Yan Liu, Yifeng Dai, Yifan Pang, Yang Jiao, Xiaoyan Ke, Wei Cui, Qingyi Zhang, Jinlong Shi, Lin Fu*

*Corresponding author voor dit werk

    OnderzoeksoutputAcademicpeer review

    33 Citaten (Scopus)
    90 Downloads (Pure)


    Acute myeloid leukemia (AML) is a hematological malignancy characterized by the proliferation of immature myeloid cells, with impaired differentiation and maturation. Pyruvate dehydrogenase kinase (PDK) is a pyruvate dehydrogenase complex (PDC) phosphatase inhibitor that enhances cell glycolysis and facilitates tumor cell proliferation. Inhibition of its activity can induce apoptosis of tumor cells. Currently, little is known about the role of PDKs in AML. Therefore, we screened The Cancer Genome Atlas (TCGA) database for de novo AML patients with complete clinical information and PDK family expression data, and 84 patients were included for the study. These patients did not undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). Univariate analysis showed that high expression of PDK2 was associated with shorter EFS (P = 0.047), and high expression of PDK3 was associated with shorter OS (P = 0.026). In multivariate analysis, high expression of PDK3 was an independent risk factor for EFS and OS (P <0.05). In another TCGA cohort of AML patients who underwent allo-HSCT (n = 71), PDK expression was not associated with OS (all P > 0.05). Our results indicated that high expressions of PDK2 and PDK3, especially the latter, were poor prognostic factors of AML, and the effect could be overcome by allo-HSCT.

    Originele taal-2English
    Pagina's (van-tot)15-21
    Aantal pagina's7
    TijdschriftCancer Gene Therapy
    Nummer van het tijdschrift1-2
    StatusPublished - feb.-2020


    Duik in de onderzoeksthema's van 'Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia'. Samen vormen ze een unieke vingerafdruk.

    Citeer dit